463 related articles for article (PubMed ID: 14523625)
1. Cerebral alterations in a MPTP-mouse model of Parkinson's disease--an immunocytochemical study.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
J Neural Transm (Vienna); 2003 Oct; 110(10):1129-44. PubMed ID: 14523625
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study.
Watanabe H; Muramatsu Y; Kurosaki R; Michimata M; Matsubara M; Imai Y; Araki T
Eur Neuropsychopharmacol; 2004 Mar; 14(2):93-104. PubMed ID: 15013024
[TBL] [Abstract][Full Text] [Related]
3. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
[TBL] [Abstract][Full Text] [Related]
4. Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice.
Yokoyama H; Takagi S; Watanabe Y; Kato H; Araki T
J Neural Transm (Vienna); 2008 Jun; 115(6):831-42. PubMed ID: 18235988
[TBL] [Abstract][Full Text] [Related]
5. Role of dopamine transporter against MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Kurosaki R; Muramatsu Y; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Metab Brain Dis; 2003 Jun; 18(2):139-46. PubMed ID: 12822832
[TBL] [Abstract][Full Text] [Related]
6. Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T
Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201
[TBL] [Abstract][Full Text] [Related]
7. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease.
Watanabe Y; Kato H; Araki T
Metab Brain Dis; 2008 Mar; 23(1):51-69. PubMed ID: 18030609
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
[TBL] [Abstract][Full Text] [Related]
9. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
10. Neuronal or inducible nitric oxide synthase (NOS) expression level is not involved in the different susceptibility to nigro-striatal dopaminergic neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) between C57BL/6 and BALB/c mice.
Ito T; Uchida K; Nakayama H
Exp Toxicol Pathol; 2013 Jan; 65(1-2):121-5. PubMed ID: 21788124
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
[TBL] [Abstract][Full Text] [Related]
12. Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice.
Aoki E; Yano R; Yokoyama H; Kato H; Araki T
Exp Mol Pathol; 2009 Feb; 86(1):57-64. PubMed ID: 19027004
[TBL] [Abstract][Full Text] [Related]
13. Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease.
Kurosaki R; Muramatsu Y; Kato H; Araki T
Pharmacol Biochem Behav; 2004 May; 78(1):143-53. PubMed ID: 15159144
[TBL] [Abstract][Full Text] [Related]
14. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice.
D'Astous M; Morissette M; Tanguay B; Callier S; Di Paolo T
Synapse; 2003 Jan; 47(1):10-4. PubMed ID: 12422368
[TBL] [Abstract][Full Text] [Related]
15. Regional and temporal expression of the peripheral benzodiazepine receptor in MPTP neurotoxicity.
Kuhlmann AC; Guilarte TR
Toxicol Sci; 1999 Mar; 48(1):107-16. PubMed ID: 10330690
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effect of the angiotensin-converting enzyme inhibitor perindopril in MPTP-treated mice.
Kurosaki R; Muramatsu Y; Imai Y; Kato H; Araki T
Neurol Res; 2004 Sep; 26(6):644-57. PubMed ID: 15327754
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
Jakowec MW; Nixon K; Hogg E; McNeill T; Petzinger GM
J Neurosci Res; 2004 May; 76(4):539-50. PubMed ID: 15114626
[TBL] [Abstract][Full Text] [Related]
18. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
19. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice.
Yano R; Yokoyama H; Kuroiwa H; Kato H; Araki T
J Mol Neurosci; 2009 Sep; 39(1-2):211-9. PubMed ID: 19199078
[TBL] [Abstract][Full Text] [Related]
20. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.
Przedborski S; Jackson-Lewis V; Yokoyama R; Shibata T; Dawson VL; Dawson TM
Proc Natl Acad Sci U S A; 1996 May; 93(10):4565-71. PubMed ID: 8643444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]